Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors

MLA

Hark Kyun Kim, et al. “Phase I and Pharmacokinetic Study of the Vascular‐disrupting Agent CKD‐516 (NOV120401) in Patients with Refractory Solid Tumors.” Pharmacology Research & Perspectives, vol. 8, no. 2, Apr. 2020. EBSCOhost, https://doi.org/10.1002/prp2.568.

APA

Hark Kyun Kim, Jeong Won Kang, Young‐Whan Park, Jung Young Kim, Minchae Kim, Soo Jin Kim, Se‐mi Kim, Keun Ho Ryu, Seonghae Yoon, Yun Kim, Joo‐Youn Cho, Keun Seok Lee, Tak Yun, Kiwon Kim, Mi Hyang Kwak, Tae‐Sung Kim, Jinsoo Chung, & Joong‐Won Park. (2020). Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors. Pharmacology Research & Perspectives, 8(2). https://doi.org/10.1002/prp2.568

Chicago

Hark Kyun Kim, Jeong Won Kang, Young‐Whan Park, Jung Young Kim, Minchae Kim, Soo Jin Kim, Se‐mi Kim, et al. 2020. “Phase I and Pharmacokinetic Study of the Vascular‐disrupting Agent CKD‐516 (NOV120401) in Patients with Refractory Solid Tumors.” Pharmacology Research & Perspectives 8 (2). doi:10.1002/prp2.568.